|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
1995-1-19
|
|
pubmed:abstractText |
A recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943) was clinically evaluated through three phases of testing in a total of 2137 volunteers. We observed the immunogenic purity of TGP-943 (phase 1), the inter-lot reproducibility of both safety and immunogenicity (phase 2), no significant side-effects, a high capability of inducing both anti-HBs and anti-pre-S2 antibodies (phases 1, 2 and 3), and an ability to induce seroconversion in the majority of vaccines who had been non-responsive to conventional hepatitis B vaccines (phases 2 and 3). In conclusion, TGP-943 is a safe and tolerable vaccine, with special merits: the ability to induce an early anti-pre-S2 response that circumvents the problem of delayed appearance of anti-HBs, and efficacy in non-responders to previous vaccination.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0264-410X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1090-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:7998418-Adolescent,
pubmed-meshheading:7998418-Adult,
pubmed-meshheading:7998418-Age Factors,
pubmed-meshheading:7998418-Amino Acid Sequence,
pubmed-meshheading:7998418-Child,
pubmed-meshheading:7998418-Female,
pubmed-meshheading:7998418-Hepatitis B Antibodies,
pubmed-meshheading:7998418-Hepatitis B Surface Antigens,
pubmed-meshheading:7998418-Hepatitis B Vaccines,
pubmed-meshheading:7998418-Humans,
pubmed-meshheading:7998418-Injections, Intramuscular,
pubmed-meshheading:7998418-Injections, Subcutaneous,
pubmed-meshheading:7998418-Male,
pubmed-meshheading:7998418-Middle Aged,
pubmed-meshheading:7998418-Molecular Sequence Data,
pubmed-meshheading:7998418-Protein Precursors,
pubmed-meshheading:7998418-Radioimmunoassay,
pubmed-meshheading:7998418-Reproducibility of Results,
pubmed-meshheading:7998418-Safety,
pubmed-meshheading:7998418-Vaccines, Synthetic
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
Safety and efficacy of a recombinant yeast-derived pre-S2 + S-containing hepatitis B vaccine (TGP-943): phase 1, 2 and 3 clinical testing.
|
|
pubmed:affiliation |
First Department of Internal Medicine, Yamanashi Medical College, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I,
Clinical Trial, Phase III
|
